AU2021377176A1 - Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof - Google Patents

Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof Download PDF

Info

Publication number
AU2021377176A1
AU2021377176A1 AU2021377176A AU2021377176A AU2021377176A1 AU 2021377176 A1 AU2021377176 A1 AU 2021377176A1 AU 2021377176 A AU2021377176 A AU 2021377176A AU 2021377176 A AU2021377176 A AU 2021377176A AU 2021377176 A1 AU2021377176 A1 AU 2021377176A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
antibody
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021377176A
Other languages
English (en)
Other versions
AU2021377176A9 (en
Inventor
Hq Han
Xiaolan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2021377176A1 publication Critical patent/AU2021377176A1/en
Publication of AU2021377176A9 publication Critical patent/AU2021377176A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021377176A 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof Pending AU2021377176A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112380P 2020-11-11 2020-11-11
US63/112,380 2020-11-11
US202063113922P 2020-11-15 2020-11-15
US63/113,922 2020-11-15
PCT/US2021/058181 WO2022103660A1 (en) 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Publications (2)

Publication Number Publication Date
AU2021377176A1 true AU2021377176A1 (en) 2023-06-22
AU2021377176A9 AU2021377176A9 (en) 2024-09-19

Family

ID=81601668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021377176A Pending AU2021377176A1 (en) 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Country Status (7)

Country Link
EP (1) EP4243931A4 (https=)
JP (1) JP2023548346A (https=)
KR (1) KR20230118573A (https=)
AU (1) AU2021377176A1 (https=)
CA (1) CA3197104A1 (https=)
MX (1) MX2023005565A (https=)
WO (1) WO2022103660A1 (https=)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142900A0 (en) * 1999-09-03 2002-04-21 Amgen Inc Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
TR201901929T4 (tr) * 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
KR20100058509A (ko) * 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
JP2011526792A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
EP2401296A1 (en) * 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
EP2826789A1 (en) * 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AU2012375257B2 (en) * 2012-03-31 2019-09-12 R-Pharm International, Limited Liability Company Osteoprotegerin derived composition and use thereof
CN105431453A (zh) * 2012-11-01 2016-03-23 艾伯维公司 稳定的双重可变结构域免疫球蛋白制剂
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6594855B2 (ja) * 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3274457A4 (en) * 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
SI4190355T1 (sl) * 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe
WO2019079762A1 (en) * 2017-10-20 2019-04-25 Children's National Medical Center METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM
AU2019394364A1 (en) * 2018-12-05 2021-06-17 The Council Of The Queensland Institute Of Medical Research Rank antagonists and uses therefor

Also Published As

Publication number Publication date
JP2023548346A (ja) 2023-11-16
KR20230118573A (ko) 2023-08-11
MX2023005565A (es) 2024-02-23
CA3197104A1 (en) 2022-05-19
WO2022103660A1 (en) 2022-05-19
EP4243931A4 (en) 2025-01-01
EP4243931A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
US20240262883A1 (en) Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
CN112638406B (zh) 白介素-2变体及其使用方法
EP3528833B1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
KR20220035122A (ko) 신규한 인터루킨-2 변이체 및 이의 이작용성 융합 분자
CN110505883A (zh) 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
RU2858732C2 (ru) Бифункциональные антагонисты активина/TGF-бета и RANKL и их применение
US20230391880A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
AU2021377176A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
RU2851121C1 (ru) Новые бифункциональные мультиспецифические антагонисты, способные ингибировать множественные лиганды семейства tgf-бета, и их применения
US20230391892A1 (en) Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof
CN116917330A (zh) 激活蛋白/TGF-β和RANKL的双功能拮抗剂及其用途
CN116801895A (zh) 新颖的能够抑制TGF-β家族多于一种配体的双功能多特异性拮抗剂及其用途
CN116635059A (zh) 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途
CN118103406A (zh) 可激活多肽复合物
HK1251588B (en) Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases

Legal Events

Date Code Title Description
SREP Specification republished